Phaseline

Companies › NeuroBiogen

NeuroBiogen: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Neurology, Metabolic and endocrine; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KDS2010–Phase 2Overweight; Mild Cognitive Impairment (MCI)Jan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07009171KDS2010Phase 2OverweightMetabolic and endocrineJan 2027
NCT07027072KDS2010Phase 2Mild Cognitive Impairment (MCI)NeurologyJun 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Shenzhen Wingor Biotechnology Corxel Pharmaceuticals Urovant Sciences MediciNova PRG Science & Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.